Vigil Neuroscience Inc (VIGL) concluded trading on Thursday at a closing price of $7.88, with 35.53 million shares of worth about $279.94 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 168.03% during that period and on May 22, 2025 the price saw a gain of about 241.13%. Currently the company’s common shares owned by public are about 46.67M shares, out of which, 22.65M shares are available for trading.
Stock saw a price change of 239.66% in past 5 days and over the past one month there was a price change of 335.36%. Year-to-date (YTD), VIGL shares are showing a performance of 363.53% which increased to 125.79% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.31 but also hit the highest price of $6.06 during that period. The average intraday trading volume for Vigil Neuroscience Inc shares is 154.55K. The stock is currently trading 198.43% above its 20-day simple moving average (SMA20), while that difference is up 274.67% for SMA50 and it goes to 193.23% higher than SMA200.
Vigil Neuroscience Inc (NASDAQ: VIGL) currently have 46.67M outstanding shares and institutions hold larger chunk of about 35.93% of that.
The stock has a current market capitalization of $367.77M and its 3Y-monthly beta is at 1.92. It has posted earnings per share of -$2.06 in the same period. It has Quick Ratio of 2.97 while making debt-to-equity ratio of 0.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for VIGL, volatility over the week remained 62.69% while standing at 28.14% over the month.
Stock’s fiscal year EPS is expected to rise by 9.84% while it is estimated to increase by 18.78% in next year. EPS is likely to grow at an annualized rate of 9.06% for next 5-years, compared to annual growth of -19.68% made by the stock over the past 5-years.
Coverage by Morgan Stanley stated Vigil Neuroscience Inc (VIGL) stock as an Underweight in their note to investors on December 19, 2023, suggesting a price target of $4 for the stock. On October 18, 2023, JMP Securities Initiated their recommendations, while on March 31, 2023, Mizuho Initiated their ratings for the stock with a price target of $15. Stock get an Outperform rating from Wedbush on September 16, 2022.
